Anthony Manning Sells 10,000 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Anthony Manning sold 10,000 shares of Monte Rosa Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the transaction, the director owned 10,000 shares in the company, valued at $231,100. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Monte Rosa Therapeutics Price Performance

NASDAQ GLUE opened at $24.02 on Thursday. The company has a 50 day simple moving average of $19.24 and a 200-day simple moving average of $18.79. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -16.23 and a beta of 1.55. Monte Rosa Therapeutics, Inc. has a 52-week low of $4.12 and a 52-week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The company had revenue of $4.21 million for the quarter, compared to analysts’ expectations of $10.95 million. On average, analysts predict that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Institutional Trading of Monte Rosa Therapeutics

Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its stake in Monte Rosa Therapeutics by 16.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after buying an additional 451 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares during the period. Royce & Associates LP grew its position in shares of Monte Rosa Therapeutics by 8.3% in the third quarter. Royce & Associates LP now owns 11,024 shares of the company’s stock valued at $82,000 after purchasing an additional 848 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of Monte Rosa Therapeutics by 11.8% in the fourth quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock worth $178,000 after purchasing an additional 1,199 shares during the period. Finally, MetLife Investment Management LLC increased its stake in shares of Monte Rosa Therapeutics by 7.5% in the fourth quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock worth $411,000 after purchasing an additional 1,831 shares during the period. 79.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Wells Fargo & Company reduced their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, March 18th. Finally, Guggenheim increased their price objective on Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $33.33.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.